Canadian Adverse Reaction Newsletter
Volume 13 - Issue 4 - October 2003
Marketed Health Products Directorate, Health Products and Food Branch
In this Issue
Bisphosphonates and ocular disorders
Fluticasone and adrenal suppression
Adhesion prevention solutions in gynecological procedures
Case presentation: intravenous immunoglobulins
Summary of Advisories
Insulin products
Scope
This quarterly publication alerts health professionals to potential signals
detected through the review of case reports submitted to Health Canada.
It is a useful mechanism to disseminate information on suspected adverse
reactions to health products occurring in humans before comprehensive
risk-benefit evaluations and regulatory decisions are undertaken. The
continuous evaluation of health product safety profiles depends on the
quality of your reports.
Reporting Adverse Reactions
Contact Health Canada
or a Regional AR Centre
free of charge
Phone: 866 234-2345
Fax: 866 678-6789
Email: cadrmp@hc-sc.gc.ca
Click here for the Adverse Reaction Reporting
Form.
Caveat: Adverse reactions (ARs) to health products are considered
to be suspicions, as a definite causal association often cannot be determined.
Spontaneous reports of ARs cannot be used to estimate the incidence of
ARs because ARs remain underreported and patient exposure is unknown.
Bisphosphonates and ocular disorders
Bisphosphonates inhibit bone resorption. Indications for their use vary
according to the individual products, but they are used primarily to prevent
or treat osteoporosis, Paget's disease of bone, tumour-induced hypercalcemia
and conditions associated with increased osteoclast activity (predominantly
lytic bone metastases and multiple myeloma). International data from spontaneous
reporting systems for visual reactions associated with bisphosphonates
suggest that, in rare instances, this class of medication can cause serious
ocular adverse effects.1
Pamidronate has been associated with ocular inflammation such as uveitis,
nonspecific conjunctivitis, episcleritis and scleritis.1
Similar disorders have been linked to alendronate, clodronate, etidronate
and risedronate.1-3 These ocular effects
were initially thought to be related to amine-bisphosphonates, which include
alendronate, pamidronate and risedronate. However, clodronate and etidronate,
both non-amine-bisphosphonates, have also been implicated.1-3
Health Canada received 27 domestic reports of suspected ocular and visual
disorders associated with bisphosphonates since their introduction to
the Canadian market to Feb. 28, 2003 (Table 1).
Of these reports, 13 involved alendronate, 5 etidronate, 6 pamidronate
and 3 risedronate. No cases of visual disorders have yet been reported
in association with clodronate or zoledronic acid in Canada. Many factors,
such as time marketed, exposure data and varying indications for the different
products, can influence reporting rates of adverse effects in spontaneous
reporting systems.
Indications of ocular inflammation may include eye pain, redness, abnormal
vision (blurred or double vision, decreased vision, "floaters") and photophobia.1,4
Although these ocular effects may be rare with bisphosphonates, health
care professionals should be aware of their possibility. The following
guidelines have been suggested for the care of patients receiving bisphosphonates:1
- Patients with visual loss or ocular pain should be referred to an
ophthalmologist.
- Nonspecific conjunctivitis seldom requires treatment and usually decreases
in intensity during subsequent exposure to a bisphosphonate.
- More than 1 ocular side effect can occur at the same time (e.g., episcleritis
in conjunction with uveitis). In some instances, the drug may need to
be discontinued in order for the ocular inflammation to resolve.
- For scleritis to resolve, even during full medical therapy, the bisphosphonate
therapy must be discontinued.
Pascale Springuel, BPharm; Marielle McMorran, BSc, BSc(Pharm), Health
Canada
References
1. Fraunfelder FW, Fraunfelder
FT. Bisphosphonates and ocular inflammation. N Engl J Med 2003;348(12):1187-8.
2. Ocular adverse effects of alendronic acid. Prescrire-Int
2001;10(53):82.
3. Fietta P, Manganelli P, Lodigiani L. Clodronate
induced uveitis. Ann Rheum Dis 2003;62(4):378.
4. Fraunfelder FW, Rosenbaum JT. Drug-induced uveitis.
Incidence, prevention and treatment. Drug Safety 1997;17(3):197-207.
Table 1: Reactions described in the 27 reports
submitted to Health Canada of suspected domestic adverse reactions (ARs)
of visual disorders associated with bisphosphonates from date marketed in
Canada to Feb. 28, 2003*
Variable |
Alendronate |
Etidronate |
Pamidronate |
Risedronate |
|
Date marketed in Canada |
1996
|
1979
|
1992
|
1999
|
Reaction terms reported (no.
of reactions) |
Abnormal vision (5), blindness
(1),
conjunctivitis (2), corneal ulceration (1), eye pain (4), iritis (2),
lacrimation abnormal (1), periorbital edema (2) |
Abnormal vision (2), blindness
(1), blindness
temporary (1), conjunctivitis (1), keratitis (1), macula lutea degeneration
(1), photopsia (1), retinal disorder (1) |
Abnormal vision (4), eye
pain (1), optic neuritis (1), periorbital edema (1), photophobia (1),
pupillary reflex impaired (1) |
Blindness (2), glaucoma
(1), ocular hemorrhage (1), retinal detachment (1) |
*These data cannot be used to determine
the incidence of ARs or to make quantitative drug safety comparisons between
products because ARs are underreported and neither patient exposure nor
the amount of time the drug was on the market has been taken into consideration.
These reactions are not limited to ocular inflammation but include
all reported visual disorder reactions. Spontaneous reports are considered
suspicions only.
Several
reaction terms may be listed per AR report. Reaction terms are based on
the "preferred term" of the World Health Organization (WHO)
Adverse Reaction Dictionary (WHOART).
Includes
blurred vision and decreased vision.
Describes
various degrees of decreased vision.
Fluticasone and adrenal suppression
Inhaled corticosteroids are highly effective for the control of asthma
and the prevention of exacerbations.1 Recently,
there have been several reports worldwide of adrenal insufficiency in
adults and children using inhaled corticosteroids.2-5
Although adrenal insufficiency can occur with any inhaled corticosteroid,
it may be more common with fluticasone because of the drug's pharmacologic
and pharmacokinetic properties, including its greater potency and hence
lower equivalent dose (half the dose of either budesonide or beclomethasone
).2,6,7
In addition, this may result from higher-than-licensed doses of fluticasone
being more widely prescribed in children than other inhaled corticosteroids5.
The Health Canada database was searched for suspected adverse reactions
involving endocrine disorders reported from Jan. 1, 1996, to Sept. 30,
2002, associated with fluticasone, budesonide and beclomethasone. There
were no Canadian case reports of suspected adrenal insufficiency associated
with the use of budesonide or beclomethasone.
There were 9 reports involving fluticasone, 5 of which involved children
aged 4-13 years (where specified). Dosages (where specified) ranged from
250 to 1100 µg/d; in 4 cases the dose exceeded 1000 µg/d.
Two patients experienced adrenal crisis; one was a boy (age unspecified),
and the other was a 72-year-old man.
Adrenal insufficiency associated with inhaled corticosteroid use can
occur because of systemic absorption of the corticosteroid and consequent
suppression of endogenous glucocorticoids, which leaves insufficient adrenal
reserve to respond to stressful stimuli (e.g., surgery, trauma and infection).2,3
Adrenal insufficiency may also result from abrupt discontinuation or noncompliance
with treatment, which leads to acute steroid deficiency.2,3
Signs and symptoms of adrenal suppression and crisis are nonspecific and
include anorexia, abdominal pain, weight loss, fatigue, headache, nausea,
vomiting, decreased level of consciousness, hypoglycemia and seizures.3,5
Clinicians are reminded that, beyond a certain limit, increasing the
dose of inhaled corticosteroids offers minimal benefit but increases the
risk of systemic adverse effects.1,7,8
Canadian asthma consensus guidelines recommend that, once best results
are achieved, the dose should be reduced at appropriate intervals to determine
the minimum dose required to maintain control.1
In addition, different inhalation techniques (e.g., chambers, inhalers
and spacers) and propellants (e.g., chlorofluorocarbon v. hydrofluoroalkane
preparations) can influence the portion of inhaled drug, and thus systemic
bioavailability.6,9
Patients and parents should be informed of the risk as well as the signs
and symptoms of adrenal suppression associated with the use of inhaled
corticosteroids. Adrenal suppression can be reversed upon reduction of
dosage. However, patients and parents should also be cautioned about the
risk of serious adverse reactions from abruptly stopping treatment.
Kimby Barton, MSc, Health Canada
References
1. Boulet LP,
Becker A, Berube D, Beveridge R, Ernst P. Inhaled glucocorticosteroids
in adults and children. Use of glucocorticosteroids in asthma. Canadian
asthma consensus group. CMAJ 1999;161(11 Suppl):S24-8.
2. Lipworth BJ. Systemic adverse effects
of inhaled corticosteroid therapy. A systematic review and meta-analysis.
Arch Intern Med 1999;159:941-55.
3. Adverse Drug Reactions Advisory Committee.
Fluticasone and adrenal crisis. Aust Adverse Drug React Bull 2003;22(2):6.
Available: http://www.health.gov.au/tga/adr/aadrb/aadr0304.htm
(accessed 2003 Aug 18).
4. Centre for Adverse Reactions Monitoring
(CARM), Medsafe New Zealand. Adrenal insufficiency, hypoglycaemia, or
seizure with fluticasone. Adverse Reactions of Current Concern
2003. Available: http://www.medsafe.govt.nz/Profs/adverse/cc.htm
(accessed 2003 Aug 18).
5. Committee on Safety of Medicines and
the Medicines Control Agency. Inhaled corticosteroids and adrenal suppression
in children. Curr Probl Pharmacovigilance 2002;28(Oct):7. Available:
http://medicines.mhra.gov.uk/aboutagency/regframework/csm/csmhome.htm (accessed 2003 Aug 18).
6. Todd GRG, Acerini CL, Ross-Russell R,
Zachra S, Warner JT, McCance D. Survey of adrenal crisis associated with
inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457-61.
7. Holt S, Suder A, Weatherall M, Cheng
S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone
propionate in adolescents and adults with asthma: meta-analysis. BMJ
2001;323:253-6.
8. Drake AJ, Howells RJ, Shield JPH, Prendiville
A, Ward PS, Crowne EC. Symptomatic adrenal insufficiency presenting with
hypoglycaemia in children with asthma receiving high dose inhaled fluticasone
propionate. BMJ 2002;324:1081-2.
9. Salvatoni A, Piantanida E, Nosetti L,
Nespoli L. Inhaled corticosteroids in childhood asthma. Long-term effects
on growth and adrenocortical function. Pediatr Drugs 2003;5(6):351-61.
Adhesion prevention solutions in gynecological procedures:
late-onset postoperative pain
IntergelTM Adhesion Prevention Solution (0.5% ferric hyaluronate
gel) is indicated in Canada for use as an intraperitoneal instillate for
the reduction of adhesions following peritoneal cavity surgery1.
It provides a transient, viscous, lubricious coating on peritoneal surfaces
following surgical procedures. The product is contraindicated in patients
with pelvic or abdominal infection. Health Canada issued a class III medical
device licence (a class III medical device has relatively higher risk
characteristics than class I and II devices; in this case, the product
is surgically invasive) for the product on Sept. 21, 1999. Since then,
there have been post-market reports of suspected late-onset postoperative
pain and repeat surgeries following onset of pain, noninfectious foreign-body
reactions and tissue adherence associated with certain gynecological procedures.
In some patients residual material was observed during surgery.
On Mar. 28, 2003, Gynecare Worldwide, a division of Ethicon, Inc., the
product distributor, issued an urgent worldwide voluntary withdrawal of
Gynecare IntergelTM Adhesion Prevention Solution and advised
that all use of the product be immediately discontinued.2
The Canadian distributor issued an equivalent urgent recall on Apr. 2,
2003.3 The Canadian recall was completed
by May 6, 2003.
One report of a serious, unexpected reaction suspected to be associated
with the product was received by Health Canada. A woman in her mid-30s
(weight 64 kg) underwent laparoscopy and left fimbrioplasty in November
2002. IntergelTM Adhesion Prevention Solution was instilled
at the end of the procedures. The following day the patient was admitted
to hospital with peritonitis-like symptoms. She was given antibiotics
empirically, and over 3 days her condition started to improve but she
was still in pain. In January 2003 she presented with pelvic pain and
was admitted to hospital for surgery. Residue of IntergelTM
Adhesion Prevention Solution was washed out. Inflammation was observed,
and many internal organs were adhered, with degradation of tissue.
The manufacturer of Gynecare IntergelTM Adhesion Prevention
Solution is currently assessing technical issues, surgical techniques
and circumstances associated with these post-market events and will communicate
the results of its findings to Health Canada.
Health Canada, as well as other regulatory agencies, is closely monitoring
the issue of acute aseptic reactions and acute foreign-body reactions
associated with the use of bioresorbable anti-adhesion barrier products,
such as SeprafilmTM, InterceedTM and SepracoatTM.
Health care professionals are encouraged to report any suspected or confirmed
similar cases of late-onset postoperative pain and repeat surgeries that
may have been associated with the use of Gynecare IntergelTM
Adhesion Prevention Solution, or cases of postoperative acute aseptic
peritonitis possibly associated with the use of other anti-adhesion products.
Any problems or complaints pertaining to medical devices should be reported
to Health Canada at the address below, or through the toll-free number
800 267-9675.
Health Products and Food Branch Inspectorate
Health Canada
Tower A, Holland Cross
11 Holland Ave., AL 3002C
Ottawa ON K1A 0K9
David F. Clapin, BSc, PhD, MPA; Philip Neufeld, PhD; Kim Dix, PEng, BASc;
Fred Lapner, MD, FRCPC, Health Canada
References
1. IntergelTM
Adhesion Prevention Solution [package insert]. Somerville (NJ): Ethicon
Inc.; Johnson & Johnson Medical Products Canada [distributor] / Chaska
(MN): Lifecore Biomedical [manufacturer]; 1998. p. 2.
2. Urgent voluntary recall of Gynecare
IntergelTM Adhesion Prevention Solution. Gynecare Worldwide;
a division of Ethicon, Inc., a Johnson & Johnson company; 2003 Mar 28.
Available: http://www.fda.gov/medwatch/SAFETY/2003/Intergel.pdf
(accessed 2003 June 25).
3. Urgent voluntary recall of Gynecare
IntergelTM Adhesion Prevention Solution. Gynecare Worldwide;
issued in Canada by Johnson & Johnson Medical Products, Markham, Ont.;
2003 Apr 2.
Case Presentation
Recent Canadian cases are selected based on their seriousness, frequency
of occurrence or the fact that the reactions are unexpected. Case presentations
are considered suspicions and are presented to stimulate reporting of
similar suspected adverse reactions.
Intravenous immunoglobulin: suspected association with an intrauterine
death
A 25-year-old woman was found to have idiopathic thrombocytopenic purpura
(ITP) during pregnancy. She had no previous history of ITP and was otherwise
healthy. Her platelet count was about 50 000 x 106/L during
pregnancy, and ultrasounds of the fetus at 12 and 20 weeks' gestation
appeared normal.
Intravenous immunoglobulin therapy was prescribed at 38 weeks' gestation
in anticipation of an epidural anesthesia, given a recent drop in the
platelet count to 43 000 x 106/L. The patient received the
first infusion of immunoglobulin between 11:05 and 17:20. A few hours
later, she noticed the absence of fetal movements. A second infusion was
started at 9:10 the following morning but was stopped 25 minutes later
when she mentioned the absence of fetal movements. An ultrasound confirmed
intrauterine death.
Autopsy revealed signs of intrauterine growth retardation and hypoxia
but no malformations. Mild maceration suggested that death might have
occurred 24 to 48 hours earlier. However, examination of the placenta
revealed multiple infarcts involving about 50% to 60% of its surface,
and although one small infarct was believed to be old, the others showed
histological changes consistent with infarcts 12 to 24 hours old.
The underlying condition that resulted in intrauterine growth retardation
may also have played a role in this case. Postpartum hematological evaluation
was negative for antiphospholipid antibodies. Although there is clinical
evidence of a possible association between intravenous immunoglobulin
therapy and thrombotic events, we are unaware of any other cases of massive
placental thrombosis following the administration of this product.
"It's Your Health": insulin products
In June 2003, Health Canada updated an "It's Your Health" document on
insulin products available in Canada, in consultation with diabetes patient
groups. The document is available on Health Canada's Web site (
http://www.hc-sc.gc.ca/iyh-vsv/med/insul_e.html ). It has
been updated to reflect concerns regarding the need for additional information
about animal insulins and their existing availability. The updated version
also includes information from a Cochrane systematic review that assessed
the efficacy and safety profile of human and animal insulins.1
Reference
1. Richter B,
Neises G. "Human" insulin versus animal insulin in people with diabetes
mellitus. Cochrane Database Syst Rev 2002;3:1-67.
Summary
of health professional and consumer advisories posted from May 31
to Aug. 31, 2003
Click here to view the advisories.
|
Date |
Product |
Subject and type |
|
Aug 19 & 18 |
Casodex®
|
Accelerated deaths using
Casodex® (bicalutamide) 150 mg in patients with
localized prostate cancer otherwise undergoing watchful waiting.
Health Canada has withdrawn its approval (Notice of Compliance
with conditions) for Casodex 150 mg. - AstraZeneca Canada Inc.
- consumer information and
health professional advisory |
July 23 |
CYPHERTM |
Coronary Stent Important
medical devices safety information regarding CYPHERTM
Coronary Stent and subacute thrombosis - Cordis Corporation
- health professional advisory |
July 18 & 17 |
GlucoNorm®
(repaglinide) and gemfibrozil |
Important safety information
on the concomitant use of GlucoNorm® (repaglinide)
and gemfibrozil - Novo Nordisk Canada Inc.
- consumer information
and health professional advisory |
July 16 & May 28 |
PremplusTM |
Important safety information
on estrogen plus progestin (PremplusTM tablets) -
Wyeth Pharmaceuticals
- consumer information and
health professional advisory |
July 17 & 11 |
TOPAMAXTM |
Important drug warning
- reports of oligohidrosis (decreased sweating) and hyperthermia
in patients treated with TOPAMAXTM (topiramate) -
Janssen Ortho, Inc.
- consumer information and
health professional advisory |
July 15 & 10 |
Paxil® |
Important drug warning
- Paxil® (paroxetine hydrochloride) should not be
used in children and adolescents under 18 years of age - GlaxoSmithKline
- consumer information and health
professional advisory |
July 7 |
Counterfeit
Lipitor® |
Health Canada advises
public of counterfeit Lipitor® in US
- consumer
information |
June 25 |
Pan Pharmaceuticals
Ltd. |
Health Canada alerts
Canadians to Pan Pharmaceuticals Ltd. recall in Australia
- consumer
information |
June 16 |
Repaglinide and gemfibrozil |
EMEA contraindicates
the concomitant use of repaglinide and gemfibrozil.
- health professional advisory |
June 9 |
Ephedra / ephedrine |
Health Canada reminds
Canadians of the dangers of Ephedra / ephedrine products
- consumer
information |
June 6 |
Empowerplus |
Health Canada is advising
Canadians not to use Empowerplus
- consumer
information |
June 5 |
Insulin products |
It's Your Health: insulin
products in Canada
- consumer
information |
May 9 |
Rapamune®
(sirolimus) |
Important drug safety
information for lung transplant patients being treated with
Rapamune® (sirolimus) - Wyeth Pharmaceuticals
- consumer information |
|
To receive the Newsletter
and Advisories free by e-mail, join
Health Canada's MedEffect e-Notice mailing list by clicking subscribe.
|
Canadian Adverse Reaction Newsletter
Marketed Health Products Directorate
AL 0201C2
Ottawa ON K1A 1B9
Tel 613 957-0337
Fax 613 957-0335
Health professionals/consumers report toll free
Tel 866 234-2345
Fax 866 678-6789
E-mail: cadrmp@hc-sc.gc.ca
Editors
Ann Sztuke-Fournier, BPharm
Marielle McMorran, BSc, BSc(Pharm)
Acknowledgements
Expert Advisory Committee on Pharmacovigilance, AR Regional Centres and
Health Canada staff
Suggestions?
Your comments are important to us. Let us know what you think by reaching
us at cadrmp@hc-sc.gc.ca
Copyright
Her Majesty the Queen in Right of Canada, 2003. This publication may be
reproduced without permission provided the source is fully acknowledged.
The use of this publication for advertising purposes is prohibited. Health
Canada does not assume liability for the accuracy or authenticity of the
information submitted in case reports.
ISSN 1499-9447; Cat no H42-4/1-13-4E
USPS periodical postage paid at Champlain, NY, and additional locations.
Aussi disponible en français.
Caveat: Adverse reactions (ARs) to health products are considered
to be suspicions, as a definite causal association often cannot be determined.
Spontaneous reports of ARs cannot be used to estimate the incidence of
ARs because ARs remain underreported and patient exposure is unknown.
|